Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Wu, Mengling; Huang, Qianrui; Xie, Yao; Wu, Xuyi; Ma, Hongbo; Zhang, Yiwen; Xia, Yong

doi:10.1186/s13045-022-01242-2

Journal of Hematology & Oncology

Table 4 Representative cell lines and animal models for PD-1/PD-L1 interaction studies in melanoma and lung cancer

From: Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Cancer type	Cancer cell line	Mouse strain	Method for establishing mouse tumor model	Immunotherapy strategy or other treatment	References
Colon cancer	CT26, SK-MEL-28, B16-F10	BALB/c mice, NSG mice	Xenograft models	Anti-PD-L1Ab	[270]
Lung cancer	A549, LL/2	C57/BL/6 mice	Intravenous (i.v.) injection	Anti-PD-1Ab	[253]
Lung cancer	HCC827	BALB/c nude mice	Xenograft models	Photothermal therapy	[271]
Lung cancer	LLC,	C57BL/6 J mice	Xenograft models	Anti-PD-1mAb, chemotherapy	[272]
Lung cancer	CMT167, LL/2, LL/2-luc-M38	C57BL/6 mice and green fluorescent protein (GFP)-expressing mice [C57BL/6-Tg(UBC-GFP)30Scha/J]	Orthotopic tumors and subcutaneous tumors	PD-1/PD-L1 antibody	[273]
Lung cancer	NCI-H460, A549	n.a	n.a	PD-L1 regulation with siRNA	[274]
Lung cancer	A549, H1299	n.a	n.a	PD-L1 knockdown with shRNA	[275]
Lung cancer	A549, PC-9	NOD/SCID mice	Patient-derived xenograft mice	PD-L1 knockdown with shRNA	[276]
Lung cancer and other cancer types	PC-3,A549, HepG2, SiHa	NU/J male mice, NSG mice	Xenograft models	CAR T cell, oncolytic adenovirus, anti-PD-L1Ab	[251]
Lung cancer and other cancer types	LLC, EL4, EL4-OVA, MC-38, MC38-OVA	C57BL/6 mice, BALB/c mice	Xenograft models	Anti-PD-L1Ab, anti-CTLA-4Ab	[277]
Lung cancer and other cancer types	NCI-H292, HCC827, OV79, A204	NSG mice, NOG mice	Xenograft models	Anti-PD-L1 monoclonal antibody LY3300054	[278]
Lung cancer and other cancer types	LLC, H1944, CALU-6, H2030, H441, H358, Hop62	C57BL/6J mice, DBA/2 mice	Xenograft models	Anti-PD-1Ab, Targeted therapy	[279]
Lung cancer and other cancer types	PC-9, SW480, MC38	C57BL/6	Xenograft models	Anti-PD-1Ab, anti-PD-L1Ab	[280]
Lung cancer and other cancer types	HT1080, A549, MCF-7, NIH:OVCAR-3, PANC-1	n.a	n.a	Anti-PD-1Ab	[281]
Lung cancer and other cancer types	A375, A549, CAKI-1, H1299, H1975, HCC827, HCT116, KU-19–19, MDA-MB-231, RKO	NSG mice	Xenograft models	Anti-PD-L1Ab	[282]
Lung cancer, breast cancer, liver cancer	A549/CDDP, MCF7/ADR, HepG2/ADR	BALB/C nude mice	Xenograft models	Anti-PD-L1Ab	[283]
Lung cancer, Melanoma and other cancer types	B16-F10, CT26, 4T1, L12, A549, H1299, PC9	C57BL/6 mice, BALB/c mice	Xenograft models, intraperitoneally (i.p.) injection	Other treatment	[284]
Lung cancer, melanoma and other cancer types	MCF-7, MDA-MB-231, HepG2, A549, A375, HeLa	n.a	n.a	Targeted therapy	[285]
Lung cancer, melanoma, colorectal cancer, breast cancer	PC-9, A375, SW116, H1975, 4T1	n.a	n.a	PD-L1 knockdown with shRNA, SiRNA, plasmid and small molecule drug(PD-L1/PD-1 inhibitor 1, BMS1166)	[286]
Lung cancer, melanoma, prostate cancer	HCC827, A549, H2228, PC9, LLC, A375, A431, SK-MEL-5, SK-MEL-28, DU145	C57BL/6	Xenograft models	Anti-PD-L1Ab, PD-L1 knockdown with SiRNA	[287]
Lung cancer, prostate cancer	NCI-H460, A549, PC-3, NCI-H1299, NCI-H446	n.a	n.a	PD-L1 detection	[288]
Lung cancer, TNBC	A549, MDA-MB-231	NSG mice	Xenograft models	Anti-CD137 × PD-L1 bispecific Ab, anti-PD-1Ab, anti-PD-L1Ab	[250]
Melanoma	A375, A431	n.a	n.a	Other treatment	[289]
Melanoma	B16-F0, B16-F1	n.a	n.a	Anti-PD-L1Ab	[290]
Melanoma	B16-PD-L1	C57BL/6 mice	Xenograft models	Chemotherapy, other treatment	[255]
Melanoma	PD-L1 KO B16-OVA	C57BL/6J mice, hPD-L1 KI mice	Xenograft models	Anti-hPD-L1Ab, anti-CD8Ab, anti-CD4Ab, anti-F4/80Ab	[291]
Melanoma	B16-F10	C57BL/6 mice	Xenograft models	Anti-PD-L1Ab	[292]
Melanoma and other cancer types	HepG2-Luc, HepG2, B16	C57BL/6 mice	Xenograft models	Other treatment	[293]
Melanoma and other cancer types	AT-3, 4T1, B16-F10, MC38,	C57BL/6 mice, Pmel-1 TCR-transgenic mice, Batf3 − / − mice, BALB/c − AnNCr mice	Xenograft models, orthotopic model	Anti-PD-L1Ab,anti-CD4Ab, anti-CD8βAb, anti-NK1.1Ab, anti-IL-12p40Ab, anti-IFN-γAb, Targeted therapy, Radiotherapy	[294]
Melanoma, lung cancer and other cancer types	B16, LLC, GL261, MC38, Pan02, MethA, CT26	C57BL/6 N and BALB/c inbred mice	Bilateral xenograft models model	Anti-PD-L1Ab	[295]
Melanoma, Cervical cancer, Colorectal cancer	HeLa, HCC827, PC3, NCI-H2023, 4T1, B16.F10, CT26	BALB/c	Xenograft models	Anti-PD-1Ab, anti-PD-L1Ab, PD1-Fc-OX40L	[296]
Melanoma, Colon cancer	MC38-hPD-L1, A375	NOG mice, human PD-L1/LAG-3 double knock-in mice	Xenograft models	Anti-PD-L1 × LAG-3 bispecific Ab, anti-PD-L1Ab	[252]
Melanoma, Colon cancer	B16, CT26	C57BL/6 mice, BALB/c mice	Genetically modified mouse model, xenograft models, intravenous (i.v.) injection	Anti-PD-1Ab	[297]
Melanoma, Colon cancer	B16-F10, CT26	C57BL/6 mice, BALB/c mice	Xenograft models	Anti-PD-L1 mAb, anti-TRP-1 mAb	[298]
NSCLC	HCC827, H1975, PC-9	BALB/c athymic nude mice	Xenograft models, i.v. injection	PD-L1 knockdown with shRNA	[254]
NSCLC	HCC827, H1975	n.a	n.a	Targeted therapy	[299]
NSCLC	A549, H460, H1975	C57/BL/6 mice	Xenograft models	PD-L1 knockout	[300]
NSCLC	A549, NCI-H23, NCI-H460, NCI-H226	n.a	n.a	PD-L1 quantification on tumor biopsies	[301]
PD-L1-positive solid tumors	K562, Jurkat, A549, NCI-H292, SKOV3, HEK293T	B-NDG mice	Xenograft dual-tumor models	CAR T cell, PD-L1 chimeric costimulatory receptor	[302]

n.a. not applicable, NSCLC non-small-cell lung cancer, Ab antibody

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com